|
July 7, 2009
ZOSANO PHARMA, INC. SECURES $30 MILLION IN NEW ROUND OF FINANCING
Funds to Support Late-stage Development of ZP-PTH for Osteoporosis June 11, 2009
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF THORSTEN VON STEIN AS CHIEF MEDICAL OFFICER
April 4, 2009
ZOSANO PHARMA, INC. PRESENTS POSITIVE PHASE 2 RESULTS OF ITS NEEDLE-FREE OSTEOPOROSIS THERAPY
- Rapid Delivery Transdermal Patch Demonstrates Increase in Lumbar Spine and Hip Bone Mineral Density - March 31, 2009
ZOSANO PHARMA, INC. TO PRESENT POSITIVE PHASE 2 RESULTS OF ITS TRANSDERMAL PATCH FOR OSTEOPOROSIS
January 19, 2009
ZOSANO PHARMA, INC. TO PRESENT AT THE 13TH ANNUAL DRUG DELIVERY PARTNERSHIPS MEETING
- Presentation to Include Update on Two New Pipeline Programs - December 9, 2008
ZOSANO PHARMA, INC. COMPLETES POSITIVE END-OF-PHASE 2 MEETING WITH FDA REGARDING ZP- PTH PATCH FOR OSTEOPOROSIS October 27, 2008
ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 OSTEOPOROSIS STUDY
ZP-PTH Patch Demonstrates Increase in Lumbar Spine and Hip Bone Mineral Density October 23, 2008
ZOSANO PHARMA, INC. TO PRESENT AT BIO INVESTOR FORUM
The presentation will be delivered at the Palace Hotel in San Francisco, Calif., on Thursday October 30th at 1:45 PM September 11, 2008
ZOSANO PHARMA, INC. ANNOUNCES POSITIVE RESULTS OF PHASE 2 TRIAL WITH PTH TRANSDERMAL PATCH IN OSTEOPOROSIS
Data To Be Presented At ACR Scientific Meeting
September 8, 2008
ZOSANO PHARMA, INC. ANNOUNCES APPOINTMENT OF GAIL SCHULZE AS CHAIR AND CEO
New Senior Management Appointments Strengthen Executive Team November 28 , 2007
Zosano Pharma, Inc. Closes Enrollment in Phase 2 Trial November 15 , 2007
Zosano Pharma, Inc. Announces Funding Close Totaling $90 Million September 27, 2007
Macroflux Announces Name Change to Zosano Pharma, Inc. May 31, 2007
Macroflux names Cory Zwerling Presidient, CEO October 10, 2006
Nomura Phase4 Ventures Announces Launch of Macroflux Corporation
|
